- Report
- February 2025
- 200 Pages
Global
From €4086EUR$4,490USD£3,503GBP
- Report
- October 2024
- 203 Pages
Global
From €7235EUR$7,950USD£6,203GBP
- Report
- December 2024
- 30 Pages
Global
From €2958EUR$3,250USD£2,536GBP
- Report
- October 2024
- 170 Pages +
Global
From €7235EUR$7,950USD£6,203GBP
- Report
- September 2024
- 343 Pages
Global
From €7235EUR$7,950USD£6,203GBP
- Report
- June 2024
- 183 Pages
Global
From €4095EUR$4,500USD£3,511GBP
- Report
- February 2025
- 135 Pages
Global
From €13647EUR$14,995USD£11,699GBP
- Report
- November 2021
- 101 Pages
Global
From €4095EUR$4,500USD£3,511GBP
- Report
- September 2022
- 30 Pages
Global
From €2958EUR$3,250USD£2,536GBP
- Report
- August 2022
- 161 Pages
Global
From €6826EUR$7,500USD£5,852GBP
- Clinical Trials
- April 2024
- 220 Pages
Global
From €2275EUR$2,500USD£1,951GBP
- Clinical Trials
- April 2024
- 70 Pages
Global
From €1365EUR$1,500USD£1,170GBP
- Clinical Trials
- April 2024
- 40 Pages
Global
From €1138EUR$1,250USD£975GBP
- Drug Pipelines
- September 2022
- 30 Pages
Global
From €2958EUR$3,250USD£2,536GBP
- Report
- October 2023
- 190 Pages
Global
From €4095EUR$4,500USD£3,511GBP
- Drug Pipelines
- July 2022
- 71 Pages
Global
From €9096EUR$9,995USD£7,798GBP
- Report
- January 2024
- 109 Pages
United States
€3185EUR$3,500USD£2,731GBP
- Report
- February 2018
- 23 Pages
Global
From €9101EUR$10,000USD£7,802GBP
- Report
- January 2025
- 105 Pages
Global
From €3500EUR$4,120USD£3,106GBP

Benralizumab is a monoclonal antibody used to treat severe asthma. It is a type of biologic drug, which works by targeting and blocking a specific protein in the body that is involved in the inflammation process. Benralizumab is administered as an intravenous infusion and is used in combination with other asthma medications. It is approved for use in adults and adolescents aged 12 years and older.
Benralizumab is used to treat severe asthma that is not adequately controlled with inhaled corticosteroids and long-acting beta-agonists. It is also used to reduce the frequency of exacerbations in patients with severe asthma. Benralizumab is a relatively new drug and is still being studied to determine its long-term safety and efficacy.
In the Benralizumab market, some of the major players include AstraZeneca, GlaxoSmithKline, Sanofi, and Teva Pharmaceuticals. Other companies involved in the market include Boehringer Ingelheim, Merck, and Novartis. Show Less Read more